# Treatment of Hot Flushes Caused by Leuprorelin 11.25 mg in Prostate Adenocarcinoma

> **NCT01011751** · PHASE3 · COMPLETED · sponsor: **Takeda** · enrollment: 311 (actual)

## Conditions studied

- Adenocarcinoma, Prostate

## Interventions

- **DRUG:** Cyproterone acetate
- **DRUG:** Medroxyprogesterone acetate
- **DRUG:** Venlafaxine
- **DRUG:** Leuprorelin
- **DRUG:** Flutamide
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01011751
- **Lead sponsor:** Takeda
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-04
- **Primary completion:** 2007-12
- **Final completion:** 2007-12
- **Target enrollment:** 311 (ACTUAL)
- **Last updated:** 2015-07-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01011751

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01011751, "Treatment of Hot Flushes Caused by Leuprorelin 11.25 mg in Prostate Adenocarcinoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01011751. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*